UNLABELLED: Erlotinib has been approved as a third-line treatment for advanced non-small-cell lung cancer (NSCLC) in British Columbia (BC). A cost-effectiveness analysis was conducted to compare costs and effectiveness in patients who received third-line erlotinib to those in a historical patient cohort that would have been eligible had erlotinib been available. METHODS: In a population of patients who have been treated with drugs for advanced NSCLC, overall survival (OS), progression-to-death survival (PTD) and probability of survival one year after end of second-line (1YS) were determined using a Kaplan-Meier survival analysis. Costs were collected retrospectively from the perspective of the BC health care system. RESULTS: Incremental mean OS was 90 days (0.25 LYG), and incremental mean cost was $11,102 (CDN 2009), resulting in a mean ICER of $36,838/LYG. Univariate sensitivity analysis yielded ICERs ranging from $21,300 to $51,700/LYG. CONCLUSION: Our analysis suggests that erlotinib may be an effective and cost-effective third-line treatment for advanced NSCLC compared to best supportive care.
UNLABELLED: Erlotinib has been approved as a third-line treatment for advanced non-small-cell lung cancer (NSCLC) in British Columbia (BC). A cost-effectiveness analysis was conducted to compare costs and effectiveness in patients who received third-line erlotinib to those in a historical patient cohort that would have been eligible had erlotinib been available. METHODS: In a population of patients who have been treated with drugs for advanced NSCLC, overall survival (OS), progression-to-death survival (PTD) and probability of survival one year after end of second-line (1YS) were determined using a Kaplan-Meier survival analysis. Costs were collected retrospectively from the perspective of the BC health care system. RESULTS: Incremental mean OS was 90 days (0.25 LYG), and incremental mean cost was $11,102 (CDN 2009), resulting in a mean ICER of $36,838/LYG. Univariate sensitivity analysis yielded ICERs ranging from $21,300 to $51,700/LYG. CONCLUSION: Our analysis suggests that erlotinib may be an effective and cost-effective third-line treatment for advanced NSCLC compared to best supportive care.
Authors: Ansgar Lange; Anne Prenzler; Martin Frank; Heiko Golpon; Tobias Welte; J-Matthias von der Schulenburg Journal: BMC Pulm Med Date: 2014-12-04 Impact factor: 3.317
Authors: Doreen A Ezeife; Eldon Spackman; Rosalyn A Juergens; Janessa J Laskin; Jason S Agulnik; Desiree Hao; Scott A Laurie; Jennifer H Law; Lisa W Le; Lesli A Kiedrowski; Barbara Melosky; Frances A Shepherd; Victor Cohen; Paul Wheatley-Price; Rachel Vandermeer; Janice J Li; Roxanne Fernandes; Aria Shokoohi; Richard B Lanman; Natasha B Leighl Journal: Ther Adv Med Oncol Date: 2022-07-26 Impact factor: 5.485